23 Jul 2018 09:00
London, 23 July 2018 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75), the multinational generic pharmaceutical company, will announce its interim financial results for the six months ended 30 June 2018 on Wednesday 15 August 2018.
A presentation and webcast for analysts will be held at 9.30am BST at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD, with registration and coffee from 9.15am.
To join via conference call please dial:
UK Toll Free Number: 020 3936 2999
US Toll Free Number: 1 855 9796 654
Standard International Access: +44 20 3936 2999
Password: 911652
The results presentation and a webcast recording of the event will be available on the Company's website at www.hikma.com or http://webcast.openbriefing.com/hikma_interim_results_2018/.
Playback facility:
A playback of the conference call will be available after the presentation.
United Kingdom - 020 3936 3001
United States - 1 845 709 8569
All other locations - + 44 20 3936 3001
Replay code: 338668
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
Susan RingdalVP Corporate Strategy and Director of Investor Relations | +44 (0)20 7399 2760/ +44 7776 477050 |
Virginia Spring Investor Relations Manager | +44 (0)20 3892 4389/ +44 7973 679502 |
FTI Consulting
Ben Atwell/Brett Pollard | +44 (0)20 3727 1000 |
About Hikma
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.
Hikma Pharmaceuticals (HIK)